PIK3CB and ovarian cancer: There are a number of actively recruiting Phase I clinical trials looking at both pan- and isoform-specific PI3K inhibitors in advanced solid tumors and in particular recurrent ovarian cancer [Table 3], as monotherapy or in combination with PARP inhibitors (olaparib or niraparib), or immunotherapy agents (tislelizumab).